Rosetta Capital

About The Fund

Rosetta Capital is a venture capital firm with a strong focus on the life sciences and medical device sectors. They are dedicated to investing in, supporting, and building innovative life sciences companies that improve patient lives. With headquarters in Buckinghamshire, United Kingdom, Rosetta Capital offers a global investment horizon and has established a track record of success, executing transactions across North America and Europe. Over the years, they have raised multiple funds and have made over 50 venture investments through direct secondary transactions, showcasing their commitment to providing flexible liquidity solutions to investors or corporations. With $0 million+ in historical commitments, Rosetta Capital has achieved numerous IPO and M&A exits, primarily on the NASDAQ and European exchanges. Their experienced team and advisors specialize in the life sciences and medical device sectors, bringing with them a wealth of knowledge in management roles, investments, transactions, and scientific acumen. The firm prides itself on empowering entrepreneurs to develop breakthrough innovations and being a reliable provider of resources that aid in building world-class healthcare companies. Delivering benefits to human health is at the core of what they do, and this is reflected in their hand-picked portfolio which includes both private and public companies, such as Oxular, JenaValve, Destiny Pharma, and Immunocore. Their strategy involves creating value by identifying undervalued assets with potential for substantial improvement and growth. Rosetta Capital's investment activities revolve around transactions that are often complex and require a nuanced understanding of the intricacies within the biotech, healthtech, medical devices, and life sciences industries – sectors that are essential for the advancement of modern medicine and healthcare services.